Open Innovation | JW Holding

R&D

WE WILL MAKE HEADWAY INTO THE GLOBAL MARKET BEYOND THE DOMESTIC MARKET BY GATHERING THE ABILITY OF JW

R&D

Open Innovation

Science & Innovation R&D Nutrition therapy R&D Diagnostics R&D

2019.09

JW Pharmaceutical exports 80 billion won worth of technology to Simcere, China.
- Concluded license-out agreement for gout treatment URC102.
- URC102, A new drug candidate effective for gout with decreased renal elimination of uric acid, demonstrated high safety and reduced level of uric acid in the blood
2019.05

60th Anniversary seminar of Korean-Denmark diplomatic relations.
- Introduction of open innovation partnership strategy with Leoparm, a global leader in the field of skin disease.
2018.10

Establishment of strategic partnerships/investments with overseas ventures discovering first-in-class drugs.
- Signed a strategic investment agreement with Argonaut developing a next-generation anticancer drug based on epigenetics
2018.08

JW Pharmaceutical exports 450 billion won worth of technology to LeoPharma.
- Concluded license-out agreement for atopic dermatitis drug candidate, JW1601, with LEO Pharma
- Introduced as "Open Innovation Case" at the 60th anniversary of Korea-Denmark diplomatic relations and received Korea Patent Technology “King Sejong” Grand Prize Award
2018.07

Collaboration research agreement on new drugs between C&C Research Laboratories and A*STAR, Singapore
- "Development of new global innovative drugs (immunological disease and anticancer drugs)" in cooperation with four research institutes under A*STAR and National Skin Centre
- Discussion of research progress / plan through the steering committee meeting twice a year as a collaboration research for three years (2018 ~ 21)
Establishment of research network with KOLs in the field of Wnt
- Held a regular symposium with the leading Wnt researchers in Korea
- Operation of the SAB (Scientific Advisory Board) composed of overseas prominent Wnt researchers

Top